TransMedics Secures Unconditional FDA IDE Approval for OCS Heart Trial

TransMedics Achieves Milestone with FDA IDE Approval for OCS Heart ENHANCE Trial

TransMedics Group, Inc., a frontrunner in the medical technology sector focused on enhancing organ transplant therapies, has reached a significant milestone by receiving the U.S. Food and Drug Administration's (FDA) full and unconditional Investigational Device Exemption (IDE) approval for its OCS Heart ENHANCE trial. This approval is pivotal for advancing cardiac care, particularly for patients facing end-stage heart failure.

The announcement, made on February 9, 2026, marks a continuation of TransMedics' commitment to innovate within the transplant field. Just a month prior, in January 2026, the company successfully garnered full approval for their Next-Generation OCS DENOVO Lung IDE trial, showcasing their progressive approach. The path to this latest achievement was a rigorous process, with the conditional IDE approval for ENHANCE having been secured in August 2025.

The OCS Heart ENHANCE trial consists of two pivotal parts. The first segment, Part A, is designed to validate the effectiveness of prolonged heart perfusion using the OCS™ Heart System. Part B shifts attention to comparing the outcomes of heart perfusion using the OCS System versus traditional static cold storage methods, particularly focusing on donation after brain death (DBD) cases. TransMedics aims to demonstrate that OCS Heart perfusion could enhance clinical outcomes, potentially broadening its applications in transplant scenarios where hearts are currently preserved for no more than four hours.

This extensive trial is expected to encompass over 650 patients across both phases, making it the largest heart preservation for transplant study globally. Waleed Hassanein, MD, President and CEO of TransMedics, emphasized the importance of this trial, stating, "With the full IDE approvals for both OCS ENHANCE Heart and DENOVO Lung trials, our focus now shifts towards executing the trial and enrolling patients. This study intends to provide robust clinical evidence demonstrating that the Generation 2 OCS Heart platform extends beyond mere preservation, acting to enhance and improve cardiac function and metabolic conditions in the process."

Particularly noteworthy is the trial's ambition to be a random controlled and blinded clinical study, a first of its kind in donor heart preservation. The objective is to underline the superiority of OCS Heart perfusion techniques compared to traditional methods, ushering in a new era of heart transplantation.

The outcomes from both the ENHANCE and DENOVO trials are anticipated to act as catalysts, accelerating the adoption of heart and lung transplant technologies in the upcoming years. TransMedics underlines that their innovative solutions are designed not only to improve organ viability but also to enhance the overall quality of life for transplant recipients.

Headquartered in Andover, Massachusetts, TransMedics is leading the charge in the evolution of organ transplant technologies. The company was established to address the growing demand for better organ preservation techniques and has continually developed solutions that meet these needs. Their patented systems allow for enhanced organ quality and viability assessments prior to surgery, promising a brighter future for patients in need.

In summary, with the full FDA IDE approval now secured, TransMedics is poised to transform heart transplantation, leveraging the capabilities of their OCS Heart System to increase the efficiency and effectiveness of organ donation practices. As they embark on this critical trial phase, the medical community watches closely, hopeful for breakthroughs that could reshape lives and improve outcomes for countless patients worldwide.